|
HR(95% Cl)
|
p-value
|
p-value
|
HR(95%Cl) p-value
|
HR(95%Cl) p-value
|
|
|
Age(≤49 vs. >49 years) |
0.71 (0.29-1.72) |
0.451 |
0.451 |
– |
– |
|
|
PARPi monotherapy (Yes vs. No) |
0.36 (0.15-0.92) |
0.032*
|
0.032*
|
0.33 (0.12-0.94) |
0.038*
|
|
|
Residual Lesions(R0 vs. R1+R2) |
0.29 (0.11-0.78) |
0.014*
|
0.014*
|
0.42 (0.15-1.17) |
0.097 |
|
|
BRCA mutation (1 vs. 2) |
0.60 (0.17-2.07) |
0.416 |
0.416 |
– |
– |
|
|
Stage at diagnosis (I or II vs. III or IV) |
0.18 (0.24-1.35) |
0.096 |
0.096 |
0.33 (0.04-2.74)- |
0.305 |
|
|
Cytoreductive surgery (NAC-IDS vs. PDS) |
0.42 (0.12-1.47) |
0.174 |
0.174 |
– |
– |
|
|
1st PFI (5-12 vs. >12 months) |
0.56
(0.23-1.38) |
0.208 |
0.208 |
– |
– |
|
|
2nd PFI (6-12 vs. >12 months) |
0.58
(0.19-1.75) |
0.334 |
0.334 |
– |
– |
|
|
CA-125 at secondary recurrence (≤70 vs. >70 U/ml) |
0.62
(0.21-1.88) |
0.400 |
0.400 |
– |
– |
|
|